Bioenvision Appoints David Beadle to its Advisory Board.

Business Editors

LONDON--(BUSINESS WIRE)--Oct. 2, 2001

Bioenvision (OTCBB:BIOV) today announced that David Beadle has been appointed to its advisory board.

Beadle is an executive director and senior pharmaceutical analyst at UBS Warburg in London. Prior to taking his position with UBS Warburg, Mr. Beadle was with ABN AMRO and formerly with Schering AG, where he worked alongside of Bioenvision's Executive VP Marketing, Dr. Stuart Smith. He has also worked at a number of major pharmaceutical companies.

Dr. Chris Wood, Bioenvision's President, said, "We are delighted to have David Beadle on our board. His extensive experience in the pharmaceutical and biotechnology industry, particularly in the oncology sector, strongly positions him to advise Bioenvision on its growth and development. He will be a key member of the board as we enhance the value of the company's products. David Beadle's considerable expertise in the marketing of prostate cancer products should prove valuable in the commercialization of Modrastane(R), which is about to commence Phase II trials at the Dana Faber Cancer Institute."

Bioenvision was founded in 1997 to develop and market compounds for the treatment of cancer. The Company has a broad pipeline of 12 products for the treatment of cancer: one product at market (Modrenal(R), for which the company has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer, eight products in clinical trials and three products in pre-clinical development. These products, derived from a number of different development platforms, include: the first drug in a new class of agents for hormone sensitive cancers, a potent agent which is proving effective in clinical trials in the treatment of acute and chronic leukemia, gene therapy products in early stages of development, a number of which have proof of principal in man, and a platform of cytostatic drugs in early stage development. In addition, these platforms also have various non-oncology indications that Bioenvision is exploring. For more information on Bioenvision please visit its website at www.bioenvision.com.

Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, risks in technology and product development; failure to successfully complete clinical trials; failure to receive market clearance from regulatory agencies; dependence on third parties and partners; and those risks described in filings made by Bioenvision with the SEC. Bioenvision disclaims any obligation to update these forward-looking statements. Investors are urged to be cautious in assessing the impact of such "forward-looking" statements.

--30--rg/ny* csm jeh

    CONTACT: Bioenvision, London
             Christopher Wood, MD 011 44 207 451 2495
                or
             H.L. Lanzet, Inc., New York
             Herbert Lanzet/DeeDee Lanzet, 212/687-0061

    KEYWORD: NEW YORK INTERNATIONAL UNITED KINGDOM
    INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL MEDICAL DEVICES
PHARMACEUTICAL MANAGEMENT CHANGES
    SOURCE: Bioenvision